Literature DB >> 9205050

Selective inhibition of estrogen-regulated gene expression in vivo by the pure antiestrogen ICI 182,780.

S M Hyder1, C Chiappetta, L Murthy, G M Stancel.   

Abstract

Estrogen-stimulated cell proliferation is thought to be mediated by the induction of growth-regulatory factors. Abnormal regulation of such factors may be associated with tumorigenesis. Two such factors, vascular endothelial growth factor and c-fos, are rapidly induced in the uterus by estrogens. We show that the induction of these transcripts by 17beta-estradiol or tamoxifen is selectively blocked by the pure antiestrogen ICI 182,780 in a dose-dependent manner. This indicates that induction of the two genes requires different levels of estrogen receptor or that their induction occurs by different mechanisms. This suggests that selective dose-dependent antagonism of estrogen-dependent transcription may be possible in target tissues and tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9205050

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Estradiol rapidly inhibits soluble guanylyl cyclase expression in rat uterus.

Authors:  J S Krumenacker; S M Hyder; F Murad
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-16       Impact factor: 11.205

2.  A+U-rich-element RNA-binding factor 1/heterogeneous nuclear ribonucleoprotein D gene expression is regulated by oestrogen in the rat uterus.

Authors:  Yukitomo Arao; Atsumi Kikuchi; Kazuhiro Ikeda; Satoshi Nomoto; Hyogo Horiguchi; Fujio Kayama
Journal:  Biochem J       Date:  2002-01-01       Impact factor: 3.857

3.  Estrogen down-regulation of the Scx gene is mediated by the opposing strand-overlapping gene Bop1.

Authors:  Yukitomo Arao; Karen Carpenter; Sylvia Hewitt; Kenneth S Korach
Journal:  J Biol Chem       Date:  2009-12-08       Impact factor: 5.157

Review 4.  Mechanisms of inhibitory aryl hydrocarbon receptor-estrogen receptor crosstalk in human breast cancer cells.

Authors:  S Safe; M Wormke; I Samudio
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

5.  ESTROGEN REPLACEMENT THERAPY FOR STROKE.

Authors:  Mibel Pabon; Cyrus Tamboli; Sarosh Tamboli; Sandra Acosta; Ike De La Pena; Paul R Sanberg; Naoki Tajiri; Yuji Kaneko; Cesar V Borlongan
Journal:  Cell Med       Date:  2014-04-10

6.  Role of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells.

Authors:  Asmaà Fritah; Cécile Saucier; Olivier De Wever; Marc Bracke; Ivan Bièche; Rosette Lidereau; Christian Gespach; Sylvain Drouot; Gérard Redeuilh; Michèle Sabbah
Journal:  Mol Cell Biol       Date:  2007-12-10       Impact factor: 4.272

7.  PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis.

Authors:  Karine Belguise; Gail E Sonenshein
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

8.  Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.

Authors:  B Linderholm; J Bergqvist; H Hellborg; U Johansson; M Linderholm; E von Schoultz; G Elmberger; L Skoog; J Bergh
Journal:  Med Oncol       Date:  2009-01-07       Impact factor: 3.064

9.  Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2.

Authors:  Xiaobo Wang; Karine Belguise; Nathalie Kersual; Kathrin H Kirsch; Nora D Mineva; Florence Galtier; Dany Chalbos; Gail E Sonenshein
Journal:  Nat Cell Biol       Date:  2007-03-18       Impact factor: 28.824

Review 10.  New insights into the molecular mechanisms underlying effects of estrogen on cholesterol gallstone formation.

Authors:  Helen H Wang; Min Liu; Deborah J Clegg; Piero Portincasa; David Q-H Wang
Journal:  Biochim Biophys Acta       Date:  2009-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.